Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Driving this transition from topical steroids to the ZORYVE portfolio will be the ... Dermatology Conference and received a ...

cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of ...

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Organon (NYSE: OGN), a global healthcare company with a ...

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

Those suffering from painful eczema are all too familiar with how the cold snap can trigger uncomfortable flare-ups, leading to a search for non-steroidal solutions due to the risk of topical ...